NCT01880567View on ClinicalTrials.gov

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

113

Participants

Timeline

Start Date

July 15, 2013

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

CCND1 PositiveCCND2 PositiveCCND3 PositiveCD20 PositiveMantle Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma

Interventions

DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01880567 - Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter